KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $9.9 billion.

  • Royalty Pharma's Total Liabilities rose 2570.31% to $9.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.9 billion, marking a year-over-year increase of 2570.31%. This contributed to the annual value of $9.9 billion for FY2025, which is 2570.31% up from last year.
  • Latest data reveals that Royalty Pharma reported Total Liabilities of $9.9 billion as of Q4 2025, which was up 2570.31% from $9.7 billion recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Total Liabilities registered a high of $9.9 billion during Q4 2025, and its lowest value of $6.1 billion during Q1 2021.
  • For the 5-year period, Royalty Pharma's Total Liabilities averaged around $7.5 billion, with its median value being $7.3 billion (2022).
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 18484.32% in 2021, then tumbled by 1359.11% in 2023.
  • Quarter analysis of 5 years shows Royalty Pharma's Total Liabilities stood at $7.3 billion in 2021, then rose by 0.29% to $7.3 billion in 2022, then fell by 13.59% to $6.3 billion in 2023, then rose by 25.13% to $7.9 billion in 2024, then rose by 25.7% to $9.9 billion in 2025.
  • Its Total Liabilities was $9.9 billion in Q4 2025, compared to $9.7 billion in Q3 2025 and $8.8 billion in Q2 2025.